Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

@article{Deangelo2017InotuzumabOI,
  title={Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.},
  author={Daniel J. Deangelo and Wendy Stock and Anthony S. Stein and Andrei R. Shustov and Michaela Liedtke and Charles A Schiffer and Erik R Vandendries and Katherine F. Liau and Revathi Ananthakrishnan and Joseph P. Boni and A. Douglas Laird and Luke Fostvedt and Hagop M Kantarjian and Anjali S. Advani},
  journal={Blood advances},
  year={2017},
  volume={1 15},
  pages={1167-1180}
}
This study evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of inotuzumab ozogamicin (InO) for CD22-positive relapsed/refractory acute lymphoblastic leukemia. In phase 1, patients received InO 1.2 (n = 3), 1.6 (n = 12), or 1.8 (n = 9) mg/m2 per cycle on days 1, 8, and 15 over a 28-day cycle (≤6 cycles). The recommended phase 2 dose (RP2D) was confirmed (expansion cohort; n = 13); safety and activity of InO were assessed in patients receiving the RP2D in phase 2… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…